Wall Street brokerages expect that Cardiff Oncology, Inc. (NASDAQ:CRDF) will report sales of $70,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Cardiff Oncology’s earnings, with the lowest sales estimate coming in at $50,000.00 and the highest estimate coming in at $80,000.00. Cardiff Oncology reported sales of $90,000.00 in the same quarter last year, which indicates a negative year over year growth rate of 22.2%. The firm is expected to announce its next quarterly earnings results on Thursday, February 25th.

On average, analysts expect that Cardiff Oncology will report full year sales of $310,000.00 for the current year, with estimates ranging from $300,000.00 to $330,000.00. For the next fiscal year, analysts anticipate that the firm will post sales of $300,000.00, with estimates ranging from $200,000.00 to $400,000.00. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Cardiff Oncology.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.01). The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.05 million. Cardiff Oncology had a negative net margin of 4,990.52% and a negative return on equity of 95.03%.

Several research firms have commented on CRDF. Maxim Group increased their price objective on shares of Cardiff Oncology from $14.00 to $20.00 in a research note on Wednesday, October 21st. ValuEngine lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research note on Monday, November 2nd. HC Wainwright began coverage on shares of Cardiff Oncology in a research note on Thursday, October 22nd. They issued a “buy” rating and a $27.00 price objective for the company. Zacks Investment Research lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, BidaskClub lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research note on Friday, December 25th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Cardiff Oncology presently has an average rating of “Buy” and a consensus price target of $23.20.

NASDAQ:CRDF opened at $17.53 on Thursday. The firm has a market cap of $619.25 million, a price-to-earnings ratio of -6.26 and a beta of 1.80. Cardiff Oncology has a 52 week low of $0.70 and a 52 week high of $25.50. The firm has a 50-day moving average price of $19.70 and a two-hundred day moving average price of $12.35.

Hedge funds have recently modified their holdings of the company. Carroll Financial Associates Inc. purchased a new stake in shares of Cardiff Oncology during the 4th quarter worth approximately $66,000. LPL Financial LLC purchased a new stake in shares of Cardiff Oncology during the 3rd quarter worth approximately $201,000. Virtu Financial LLC purchased a new stake in shares of Cardiff Oncology during the 3rd quarter worth approximately $292,000. Kestra Private Wealth Services LLC purchased a new stake in shares of Cardiff Oncology during the 3rd quarter worth approximately $421,000. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Cardiff Oncology during the 3rd quarter worth approximately $568,000. Institutional investors own 52.97% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin.

See Also: How Buying a Call Option Works

Get a free copy of the Zacks research report on Cardiff Oncology (CRDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.